Stephen Shrewsbury

Stephen Shrewsbury

Chief Medical Officer

Stephen qualified in Medicine from Liverpool, UK and spent 13 years in clinical practice. He became lecturer at the National Respiratory Training Center before joining Allen & Hanburys in 1993. In 2000, he moved to the US to lead Glaxo’s inhaled fluticasone and Upper Respiratory Inflammation Disorders programs, before moving to Seattle to lead Chiron’s Inhaled Antibiotic Core Team. In 2005, he joined MAP to run clinical development for 4 inhaled drug programs (notably DHE in migraine), participating in their IPO and becoming their CMO. Steve was subsequently CMO to AVI BioPharma (now Sarepta) and most recently to Aquinox Pharmaceuticals in Vancouver, BC.